Archives of Pharmacal Research

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Synthesis and Properties of 5-Aminosalicyl-taurine as a Colon-specific Prodrug of 5-Aminosalicylic Acid

  • Jung, Yun-Jin (Department of Cell ＆ Cancer Biology, Medicine Branch, Medical Center) ;
  • Kim, Hak-Hyun (College of Pharmacy, Pusan National University) ;
  • Kong, Hye-Sik (College of Pharmacy, Pusan National University) ;
  • Kim, Young-Mi (College of Pharmacy, Pusan National University)
  • Published : 2003.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

5-Aminosalicylic acid (5-ASA) is an active ingredient of therapeutic agents used for Crohn s disease and ulcerative colitis. Because it is absorbed rapidly and extensively in the upper intestine, delivery of the agent specifically to the colon is necessary. We selected taurine as a colon-specific promoiety and designed 5-aminosalicyltaurine (5-ASA-Tau) as a new colon-specific prodrug of 5-aminosalicylic acid (5-ASA). It was expected that introduction of taurine would restrict the absorption of the prodrug and show additive effect to the anti-inflammatory action of 5-ASA after hydrolysis. 5-ASA-Tau was prepared in good yield by a simple synthetic route. The apparent partition coefficient of 5-ASA-Tau in 1-octanol/pH 6.8 phosphate buffer or $CHCl_3$/pH 6.8 phosphate buffer was 0.10 or 0.18, respectively, at $37^{\circ}C$. To determine the chemical and biochemical stability in the upper intestinal environment, 5-ASA-Tau was incubated in pH 1.2 and 6.8 buffer solutions, and with the homogenates of tissue and contents of stomach or small intestine of rats at $37^{\circ}C$. 5-ASA was not detected from any of the incubation medium with no change in the concentration of 5-ASA-Tau. On incubation of 5-ASA-Tau with the cecal and colonic contents of rats, the fraction of the dose released as 5-ASA was 45% and 20%, respectively, in 8 h. Considering low partition coefficient and stability in the upper intestine, 5-ASA-Tau might be nonabsorbable and stable in the upper intestine. After oral administration, it would be delivered to the colon in intact form and release 5-ASA and taurine. These results suggested 5-ASA-Tau as a promising colon-specific prodrug of 5-ASA.

Keywords

References

  1. Brown, J. P., McGarraugh, G. V., Parkinson, T. M., Wingard, R. E., and Onderdonk, A. B., A polymeric drug for treatment of inflammatory bowel disease. J. Med. Chem., 26, 1300-1307 (1983) https://doi.org/10.1021/jm00363a015
  2. Crotty, B. and Jewel, J. P., Drug therapy of ulcerative colitis. Br. J. Clin. Pharmaco., 34, 189-198 (1992) https://doi.org/10.1111/j.1365-2125.1992.tb04124.x
  3. Davis, S. S., Overcoming barriers to the oral administration of peptide drugs. Trends in Pharmacol. Sci., 11, 353-355 (1990) https://doi.org/10.1016/0165-6147(90)90174-7
  4. Gurujeyalakshmi, G., Wang, Y., and Giri, S. N., Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-B in mice. J. Pharmacol. Exp. Ther., 293 (1), 82-90 (2000)
  5. Istran, C., Gabor, S., and Ferene, S., Glycosides of 5-amino-salicylic acid. Magy. Kem. FOLY., 97, 143-147 (1991)
  6. Jung, Y. J., Lee, J. S., and Kim, Y. M., Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid. J. Pharm. Sci., 89, 594-602 (2000) https://doi.org/10.1002/(SICI)1520-6017(200005)89:5<594::AID-JPS5>3.0.CO;2-8
  7. Jung, Y. J., Lee, J. S., and Kim, Y. M., Colon-specific prodrug of 5-aminosalicylic acid: Synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid. J. Pharm. Sci., 90, 1767-1775 (2001) https://doi.org/10.1002/jps.1126
  8. Kopeckova, P. and Kopecek, J., Release of 5-aminosalicylic acid from bioadhesive N-(2-hydroxypropyl) methacrylamide copolymers by azoreductases in vitro. Makromol. Chem., 191, 2037-2045 (1990) https://doi.org/10.1002/macp.1990.021910906
  9. Novis, B. H., Korzets, Z., Chen, P., and Bernheim, J., Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br. Med. J., 296, 1442-1442 (1988)
  10. Podolsky, D. K., Inflammatory bowel disease (1). New Eng. J. Med., 325 (13), 928-37 (1991) https://doi.org/10.1056/NEJM199109263251306
  11. Saffran, M., Oral colon-specific drug-delivery with emphasis on insulin. In: Friend, DR, editor. Oral Colon Specific Drug Delivery, Boca Raton, FL: CRC Press. p 115-142 (1992)
  12. Saffran, M., Kumar, G. S., Savariar, C., Burnham, J. C., Williams, F., and Neckers, D. C., A new approach to the oral administration of insulin and other peptide drugs. Science, 233, 1081-1084 (1986) https://doi.org/10.1126/science.3526553
  13. Scheline, R. R., Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacological Review, 25(4), 451-523 (1973)
  14. Schuller-Levis, G., Quinn, M. R., Wright, C., and Park, E., Taurine protects against oxidant-induced lung injury: Possible mechanism(s) of action. Adv. Exp. Med. Biol., 359, 31-39 (1994) https://doi.org/10.1007/978-1-4899-1471-2_4
  15. Son, M. W., Ko, J. I., Kim, W. B., Kang, H. K., and Kim, B. K., Taurine can ameliorate inflammatory bowel disease in rats. Adv. Exp. Med. Biol., 442, 291-298 (1998) https://doi.org/10.1007/978-1-4899-0117-0_37
  16. Wilding, I. R., Davis, S. S., and OHagan, D. T., Targeting of drugs and vaccines to the Gut. Pharmacol. Ther., 62, 97-124 (1994) https://doi.org/10.1016/0163-7258(94)90006-X
  17. Zhou, S. Y., Fleisher, D., Pao, L. H., Winward, U. B., and Zimmerman E. M., Intestinal metabolism and transport of 5-aminosalicylate. Drug Metabolism and disposition, 27, 479-485 (1999)